R. Wendel Naumann, MD
Director Minimally Invasive Surgery - Gyn Onc
Levine Cancer Institute
Division of Gynecologic Oncology
309 E. Morehead St
Apt 922
Charlotte,
NC
USA
28202
Papers:
234 - Poster Session A
Reliability and reproducibility of 99mTc-etarfolatide for identification of patient folate receptor status
446 - Poster Session B
Trial in Progress: A randomized double-blind phase 3 trial comparing vintafolide + pegylated liposomal doxorubicin (PLD) versus PLD + placebo in patients with platinum-resistant ovarian cancer (PROCEED)
448 - Poster Session B
CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial
449 - Poster Session B
Adverse event profile by folate receptor status for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer
Hands On Lab: Conventional Laproscopic Proctors
Faculty
Introduction